Advertisement

The Body: The Complete HIV/AIDS Resource
Sign up for free e-mail updates!The Body en Espanol
Please Note: Due to volume considerations, not all questions can be answered. Questions most likely to be answered will be those of general interest to a broad group of visitors to this forum. Questions pertaining to a specific case; requests for diagnosis, medical advice, or second opinion; or requests for opinions about untested alternative therapies will generally not be answered.

This Forum is made possible in part by Gilead and GlaxoSmithKline.

Ask the Experts about Choosing Your Meds
Recent AnswersAsk a Question

 

which combo leaves me with more options?
Nov 21, 2005

i have never taken meds...my tcells are 190 and my VL is 3,000 my choice is between sustive/truvada or viramune/epzicom. which drug is better for sequencing? does either combo have less side effects as far as loss or gain of fat? thank you and my best to you guys on the body...

Response from Dr. Wohl

Truvada = tenofovir + FTC Epzicom = abacavir + 3TC

The good news is that the overwhelming majority of people taking either regimen can expect to get a viral load that becomes undetectable. Your viral load is low which makes it almost a shoe-in for a drop to less than 50 copies.

So, I would not be too worried about failure. If you can't help it, then rest assured that the most likely mutations that would develop with each regimen would be the same - namely the M184V mutation confering resistance to 3TC and FTC and the K103N mutation leading to very reduced viral susceptibility to Sustiva and Viramune.

With prolonged on going replication of HIV in the face of drug treatment you could start to get mutations to the thrid drug in each regimen. For Truvada, resistance to tenofovir could develop although this is rare in clinical trials. The K65R mutation reduces the effectiveness of tenofovir and most all other drugs in the nucleoside (NRTI) class. Resistance to the abacavir in Epzicom typically involves development of the L74V mutation which is not as bad and leaves a couple of more NRTI options for salvage.

I think the differences as far as sequencing here, though, are pretty minimal given most people do not virologically fail these meds when taken faithfully and that mutations to the tenofovir and abacavir are the most rare and usually the last to emerge. Clinical trial data as well as tolerability, frequency of dosing, pill count and similar convenience issues woul dbe more important in my calculus of which to start.

DW



Terms of Use
Please remember that this forum is designed for educational purposes only, and experts are not engaged through this forum in rendering legal or medical advice or professional services. Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither The Body nor any sponsor is the publisher or speaker of posted visitors' questions or the experts' material.

Questions and messages posted to this forum are not statements of advice, opinion, or information of The Body, Body Health Resources Corporation or any sponsor of this forum. While neither The Body nor Body Health Resources Corporation regularly reviews posted content, we reserve the right to delete, move, or edit postings if we deem it appropriate under the circumstances. Visitors submitting questions remain solely responsible for the content of their messages.

Information provided by experts is general only and should not be used for diagnosing or treating a health problem or a disease, or relied upon as legal or other professional advice. This information is not a substitute for professional advice or care. If you have or suspect you may have a health or legal problem, you should consult your own health care provider or your attorney.

Copyright notice.

Advertisement